GlassScriptPhysician profile
Stephen Robert Chow
NPI 1558774174
$9,341.55
in general payments reported to CMS, 2019-2025
31 companies · $2,567 in 2025
The $2,567 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,188 · 2020: $792 · 2021: $1,016 · 2022: $982 · 2023: $767 · 2024: $1,029 · 2025: $2,567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,204 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,203.88 |
| Education | $159.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,982.22 | 2019-2025 | Skyrizi, Rinvoq |
| Boston Scientific Corporation | $1,732.26 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $990.68 | 2020-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $864.92 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Gilead Sciences, INC. | $423.29 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $389.07 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Olympus America INC. | $251.78 | 2020-2021 | |
| Madrigal Pharmaceuticals | $228.32 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $226.48 | 2022-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $221.94 | 2019-2024 | Ocaliva |
| Qol Medical, LLC | $213.64 | 2024-2025 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $209.14 | 2023-2025 | Dupixent |
| Pfizer INC. | $198.66 | 2019-2025 | |
| Celltrion USA INC. | $188.59 | 2024-2025 | Vegzelma |
| Braintree Laboratories, INC. | $173.56 | 2021-2023 | Sutab, Suflave |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $169.57 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $147.41 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $126.54 | 2025 | |
| Merck Sharp & Dohme LLC | $121.95 | 2021-2024 | Dificid |
| Lilly USA, LLC | $120.18 | 2024-2025 | Omvoh |
| Janssen Scientific Affairs, LLC | $83.85 | 2022 | |
| Aimmune Therapeutics, INC. | $52.11 | 2025 | Zenpep, Vowst |
| Ipsen Biopharmaceuticals, INC | $40.73 | 2025 | Iqirvo |
| Tersera Therapeutics LLC | $38.32 | 2024 | Xermelo |
| Shire North American Group INC | $36.77 | 2019 | |
| Redhill Biopharma INC. | $28.86 | 2020 | |
| Sanofi-Aventis U.S. LLC | $21.40 | 2021 | |
| Intra-Sana Laboratories | $18.37 | 2021 | |
| Ferring Pharmaceuticals INC. | $14.37 | 2025 | Clenpiq |
| Conmed Corporation | $13.81 | 2023 | Conmed Biliary |
| Ironwood Pharmaceuticals, INC | $12.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Chow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.